Cassava CEO Remi Barbier
August 27, 2021 09:23 AM EDTUpdated 10:53 AM
R&D

The Cas­sa­va saga con­tin­ues as test­ing part­ner de­nies prepar­ing taint­ed Alzheimer's da­ta

Kyle Blankenship

The news keeps get­ting worse over at Cas­sa­va Sci­ences.

In a state­ment Fri­day, test­ing com­pa­ny Quan­ter­ix de­nied in­ter­pret­ing or prepar­ing key …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times